Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update - GlobeNewswire

Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update  GlobeNewswire

Phase 2 trial of subcutaneously administered MarzAA met primary endpoint of reduction in annualized bleed rate demonstrating safety and clinical efficacy, with ...